Literature DB >> 27847355

Crystal Structure of the Marburg Virus VP35 Oligomerization Domain.

Jessica F Bruhn1, Robert N Kirchdoerfer1, Sarah M Urata2, Sheng Li2, Ian J Tickle3, Gérard Bricogne3, Erica Ollmann Saphire4,5.   

Abstract

Marburg virus (MARV) is a highly pathogenic filovirus that is classified in a genus distinct from that of Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus, respectively). Both viruses produce a multifunctional protein termed VP35, which acts as a polymerase cofactor, a viral protein chaperone, and an antagonist of the innate immune response. VP35 contains a central oligomerization domain with a predicted coiled-coil motif. This domain has been shown to be essential for RNA polymerase function. Here we present crystal structures of the MARV VP35 oligomerization domain. These structures and accompanying biophysical characterization suggest that MARV VP35 is a trimer. In contrast, EBOV VP35 is likely a tetramer in solution. Differences in the oligomeric state of this protein may explain mechanistic differences in replication and immune evasion observed for MARV and EBOV. IMPORTANCE: Marburg virus can cause severe disease, with up to 90% human lethality. Its genome is concise, only producing seven proteins. One of the proteins, VP35, is essential for replication of the viral genome and for evasion of host immune responses. VP35 oligomerizes (self-assembles) in order to function, yet the structure by which it assembles has not been visualized. Here we present two crystal structures of this oligomerization domain. In both structures, three copies of VP35 twist about each other to form a coiled coil. This trimeric assembly is in contrast to tetrameric predictions for VP35 of Ebola virus and to known structures of homologous proteins in the measles, mumps, and Nipah viruses. Distinct oligomeric states of the Marburg and Ebola virus VP35 proteins may explain differences between them in polymerase function and immune evasion. These findings may provide a more accurate understanding of the mechanisms governing VP35's functions and inform the design of therapeutics.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Ebola virus; Marburg virus; RNA-dependent RNA polymerase; VP35; X-ray crystallography; coiled coil; filovirus; oligomerization; phosphoprotein

Mesh:

Substances:

Year:  2017        PMID: 27847355      PMCID: PMC5215338          DOI: 10.1128/JVI.01085-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Dissection of individual functions of the Sendai virus phosphoprotein in transcription.

Authors:  M C Bowman; S Smallwood; S A Moyer
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

3.  Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription.

Authors:  Peggy Möller; Nonia Pariente; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Authors:  Parameshwaran Ramanan; Megan R Edwards; Reed S Shabman; Daisy W Leung; Ariel C Endlich-Frazier; Dominika M Borek; Zbyszek Otwinowski; Gai Liu; Juyoung Huh; Christopher F Basler; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

5.  Descriptive analysis of Ebola virus proteins.

Authors:  L H Elliott; M P Kiley; J B McCormick
Journal:  Virology       Date:  1985-11       Impact factor: 3.616

6.  Integration, scaling, space-group assignment and post-refinement.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13

10.  phenix.mr_rosetta: molecular replacement and model rebuilding with Phenix and Rosetta.

Authors:  Thomas C Terwilliger; Frank Dimaio; Randy J Read; David Baker; Gábor Bunkóczi; Paul D Adams; Ralf W Grosse-Kunstleve; Pavel V Afonine; Nathaniel Echols
Journal:  J Struct Funct Genomics       Date:  2012-03-15
View more
  23 in total

Review 1.  How order and disorder within paramyxoviral nucleoproteins and phosphoproteins orchestrate the molecular interplay of transcription and replication.

Authors:  Sonia Longhi; Louis-Marie Bloyet; Stefano Gianni; Denis Gerlier
Journal:  Cell Mol Life Sci       Date:  2017-06-09       Impact factor: 9.261

2.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

3.  Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody.

Authors:  Parmeshwar Amatya; Nicole Wagner; Gang Chen; Priya Luthra; Liuqing Shi; Dominika Borek; Alevtina Pavlenco; Henry Rohrs; Christopher F Basler; Sachdev S Sidhu; Michael L Gross; Daisy W Leung
Journal:  ACS Infect Dis       Date:  2019-06-04       Impact factor: 5.084

4.  Topological control of cytokine receptor signaling induces differential effects in hematopoiesis.

Authors:  Kritika Mohan; George Ueda; Ah Ram Kim; Kevin M Jude; Jorge A Fallas; Yu Guo; Maximillian Hafer; Yi Miao; Robert A Saxton; Jacob Piehler; Vijay G Sankaran; David Baker; K Christopher Garcia
Journal:  Science       Date:  2019-05-23       Impact factor: 47.728

Review 5.  Mechanisms of Non-segmented Negative Sense RNA Viral Antagonism of Host RIG-I-Like Receptors.

Authors:  Daisy W Leung
Journal:  J Mol Biol       Date:  2019-06-14       Impact factor: 5.469

6.  Vesicular Stomatitis Virus Phosphoprotein Dimerization Domain Is Dispensable for Virus Growth.

Authors:  Francine C A Gérard; Marc Jamin; Martin Blackledge; Danielle Blondel; Jean-Marie Bourhis
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

7.  Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide Reveals a Conserved Drug Target for Filovirus.

Authors:  Tengfei Zhu; Hao Song; Ruchao Peng; Yi Shi; Jianxun Qi; George F Gao
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

8.  Structural and Functional Characterization of the Phosphoprotein Central Domain of Spring Viremia of Carp Virus.

Authors:  Zhao-Xi Wang; Shu-Bo Liu; Hongxin Guan; Long-Feng Lu; Jia-Gang Tu; Songying Ouyang; Yong-An Zhang
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

9.  Conservation of Structure and Immune Antagonist Functions of Filoviral VP35 Homologs Present in Microbat Genomes.

Authors:  Megan R Edwards; Hejun Liu; Reed S Shabman; Garrett M Ginell; Priya Luthra; Parmeshwaran Ramanan; Lisa J Keefe; Bernd Köllner; Gaya K Amarasinghe; Derek J Taylor; Daisy W Leung; Christopher F Basler
Journal:  Cell Rep       Date:  2018-07-24       Impact factor: 9.423

Review 10.  Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family.

Authors:  Adam J Hume; Elke Mühlberger
Journal:  J Mol Biol       Date:  2019-06-29       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.